文献速递心力衰竭与心肌病

自动化高危 NT-proBNP 通路在心力衰竭管理中的可行性与结局

Feasibility and outcomes of an automated high-alert NT-proBNP pathway
RSS 订阅 · Open Heart

该研究评估了电子病历中嵌入的自动化 NT-proBNP 高危预警通路,纳入 12 个月内所有 NT-proBNP 结果大于 5000 pg/mL 的患者并自动转诊心衰团队。结果显示该通路可行,43 名新诊断门诊患者中位审核时间为 2 天,70% 达到 48 小时目标,治疗后症状与心功能改善。

要点

  • NT-proBNP 大于 5000 pg/mL 时自动转诊可识别极高危心衰患者。
  • 入组患者中位审核时间 2 天,70% 达到 48 小时快速评估目标。
  • HFrEF 患者 12 周时平均左室射血分数由 27% 提升至 45%。

核心结论

  • 自动化高阈值 NT-proBNP 通路可行,可识别极高危患者并实现快速治疗优化。

研究设计与样本

  • 单中心前瞻性研究,纳入电子病历中 12 个月内所有 NT-proBNP 大于 5000 pg/mL 的结果并自动触发心衰团队转诊。
  • 设置回顾性对照队列,纳入实施前 12 个月内门诊 NT-proBNP 大于 5000 pg/mL 且不归心衰科管理的患者。

主要发现

  • 12 个月内共产生 889 例转诊,其中住院 417 例(47%)、已知门诊心衰 370 例(42%)、不适合随访 59 例(7%)、新入组 43 例(5%)。
  • 入组患者中位审核时间 2 天,70% 达到 48 小时目标;平均年龄 81 岁,56% 为男性,中位 NT-proBNP 为 7480 pg/mL。
  • 入组患者诊断为 HFrEF 21 例(49%)、HFmrEF 7 例(16%)、HFpEF 10 例(23%)、重度主动脉瓣狭窄 4 例(10%)、新发房颤 4 例(10%)。
  • 入组患者 12 周时住院率为 36%、死亡率为 8%;回顾性队列为 35% 和 12%。

关键数值与推荐

  • 转诊触发阈值为 NT-proBNP >5000 pg/mL。
  • 入组患者 12 周时 62% 的纽约心功能分级改善至少一级。
  • HFrEF 患者 12 周时平均左室射血分数由 27% 提升至 45%。

临床怎么用

  • 电子病历中嵌入 NT-proBNP 高阈值自动转诊功能,有助于高危患者快速接受心衰专科评估和超声心动图检查。
  • 对 NT-proBNP 显著升高且无心衰诊断的门诊患者,可在 48 小时内启动专科审核和治疗优化。

局限性

  • 回顾性对照队列非同期随机对照,两组间不可直接进行因果比较。
  • 研究仅在单中心开展,入组的新诊断门诊患者样本较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background NT-proBNP is a key biomarker in heart failure (HF). Patients with markedly elevated levels are at high risk of adverse outcomes but experience delays in specialist care. Evidence on the impact of an automated, high-threshold NT-proBNP referral pathway embedded in electronic patient records is limited. Methods All NT-proBNP results >5000 pg/mL over a 12-month period triggered automatic HF team referral. Referrals were categorised as inpatients, outpatients with known HF, outpatients not suitable for follow-up or new outpatients without a diagnosis of HF who were eligible for enrolment. Eligible patients were offered echocardiography and review within 48 hours, with treatment and outcome data collected prospectively. A retrospective comparator cohort included all outpatient NT-proBNP results >5000 pg/mL from patients not known to the HF service in the 12 months before implementation. Results Over 12 months, 889 referrals were generated: 417 (47%) inpatients, 370 (42%) known outpatients, 59 (7%) not appropriate and 43 (5%) enrolled. Median time to review was 2 days, with 70% meeting the 48-hour target. Among enrolled patients (mean age 81, 56% male, median NT-proBNP 7480 pg/mL), HF with reduced ejection fraction (HFrEF) was diagnosed in 21 (49%), HF with mildly reduced ejection fraction in seven (16%), HF with preserved ejection fraction in 10 (23%) and severe aortic stenosis or new atrial fibrillation in four each (10%). At 12 weeks, 62% of patients had improved by at least one New York Heart Association class, and mean left ventricular ejection fraction increased from 27% to 45% in those with HFrEF. At 12 weeks, admission and mortality were 36% and 8%, respectively, compared with 35% and 12% in the retrospective cohort (n=60). Conclusion An automated high-threshold NT-proBNP pathway is feasible and identifies very high-risk patients. Enrolled patients had rapid therapy optimisation, with observed improvements in symptoms and cardiac function.

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Feasibility and outcomes of an automated high-alert NT-proBNP pathway

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。